The Group’s in-licensed product Adasuve® (Loxapine for Inhalation) obtained Drug Registration Certificate

28 November 2023, Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", HKEx:00950) announced that the Drug Registration Certificate for Adasuve® (Loxapine for Inhalation) had been obtained from the China National Medical Products Administration (“NMPA”) for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

The release as fetched from its publisher. leespharm.com ↗